Noradrenergic cell specific gene transfer with neuronal nitric oxide synthase reduces cardiac sympathetic neurotransmission in hypertensive rats

Hypertension

Volumn 50, Issue 1, 2007, Pages 69-74

  Li, Dan ^a   Wang, Lijun ^a   Lee, Chee Wan ^a   Dawson, Tom A ^a   Paterson, David J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Autonomic nervous system; Cyclic GMP; Gene transfer; Hypertension; Nitric oxide; Norepinephrine

Indexed keywords

ADENOVIRUS VECTOR; CYCLIC GMP; ENHANCED GREEN FLUORESCENT PROTEIN; GUANYLATE CYCLASE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; NORADRENALIN;

ADRENERGIC TRANSMISSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; GENE TARGETING; GENETIC CODE; GENETIC TRANSDUCTION; HEART RIGHT ATRIUM; HYPERTENSION; IMMUNOHISTOCHEMISTRY; ISOLATED HEART; MALE; NONHUMAN; NORADRENALIN RELEASE; NORADRENERGIC NERVE; PRIORITY JOURNAL; PROMOTER REGION; RAT; SPONTANEOUSLY HYPERTENSIVE HEART FAILURE RAT; STATISTICAL ANALYSIS; STIMULATION; SYMPATHETIC TONE; TISSUE LEVEL; TREATMENT DURATION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CYCLIC GMP; ENZYME INHIBITORS; GENE TRANSFER TECHNIQUES; HEART; HEART ATRIA; HYPERTENSION; MALE; MYOCARDIUM; NEURONS; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE TYPE I; NITROPRUSSIDE; NOREPINEPHRINE; OXADIAZOLES; PROMOTER REGIONS (GENETICS); QUINOXALINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RATS, SPRAGUE-DAWLEY; SUBSTRATE SPECIFICITY; SYMPATHETIC NERVOUS SYSTEM; SYNAPTIC TRANSMISSION;

EID: 34250830359     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.088591     Document Type: Article

References (41)

1. Sendeski MM, Consolim-Colombo FM, Leite CC, Rubira MC, Lessa P, Krieger EM. Increased sympathetic nerve activity correlates with neurovascular compression at the rostral ventrolateral medulla. Hypertension. 2006;47:988-995.
2. Huggett RJ, Burns J, Mackintosh AF, Mary DA. Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension. 2004;44:847-852.
3. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation. 2004;110:1308-1312.
4. Flaa A, Mundal HH, Eide I, Kjeldsen S, Rostrup M. Sympathetic activity and cardiovascular risk factors in young men in the low, normal, and high blood pressure ranges. Hypertension. 2006;47:396-402.
5. Fisher LD, Tucker DC. Air jet noise exposure rapidly increases blood pressure in young borderline hypertensive rats. J Hypertens. 1991;9:275-282.
6. Vonend O, Okonek A, Stegbauer J, Habbel S, Quack I, Rump LC. Renovascular effects of sympathetic cotransmitters ATP and NPY are age-dependent in spontaneously hypertensive rats. Cardiovasc Res. 2005;66:345-352.
7. Krukoff TL. Central regulation of autonomic function: no brakes? Clin Exp Pharmacol Physiol. 1998;25:474-478.
8. Danson EJ, Choate JK, Paterson DJ. Cardiac nitric oxide: emerging role for nNOS in regulating physiological function. Pharmacol Ther. 2005;106:57-74.
9. Mohan RM, Heaton DA, Danson EJF, Krishnan SPR, Cai S, Channon KM, Paterson DJ. Neuronal nitric oxide synthase gene transfer promotes cardiac vagal gain of function. Circ Res. 2002;91:1089-1091.
10. Wehling-Henricks M, Jordan MC, Roos KP, Deng B, Tidball JG. Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum Mol Genet. 2005;14:1921-1933.
11. Schwarz P, Diem R, Dun NJ, Forstermann U. Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ Res. 1995;77:841-848.
12. Choate JK, Paterson DJ. Nitric oxide inhibits the positive chronotropic and inotropic responses to sympathetic nerve stimulation in the isolated guinea-pig atria. J Auton Nerv Syst. 1999;75:100-108.
13. Mohan RM, Golding S, Paterson DJ. Intermittent hypoxia modulates nNOS expression and heart rate response to sympathetic nerve stimulation. Am J Physiol Heart Circ Physiol. 2001;281:H132-H138.
14. Ruetten H, Zabel U, Linz W, Schmidt HH. Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res. 1999;85:534-541.
15. Heaton DA, Lei M, Li D, Golding S, Dawson TA, Mohan RM, Paterson DJ. Remodeling of the cardiac pacemaker L-type calcium current and its beta-adrenergic responsiveness in hypertension after neuronal NO synthase gene transfer. Hypertension. 2006;48:443-452.
16. Isner JM. Myocardial gene therapy. Nature. 2002;415:234-239.
17. Channon KM, Blazing MA, Shetty GA, Potts KE, George SE. Adenoviral gene transfer of nitric oxide synthase: High level expression in human vascular cells. Cardiovasc Res. 1996;32:962-972.
18. Qian H, Neplioueva V, Shetty GA, Channon KM, George SE. Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation. 1999;99:2979-2982.
19. Wang L, Li D, Plested CP, Dawson T, Teschemacher AG, Paterson DJ. Noradrenergic neuron-specific overexpression of nNOS in cardiac sympathetic nerves decreases neurotransmission. J Mol Cell Cardiol. 2006;41:364-370.
20. Oe K, Sperlagh B, Santha E, Matko I, Nagashima H, Foldes FF, Vizi ES. Modulation of norepinephrine release by ATP-dependent K(+-)-channel activators and inhibitors in guinea-pig and human isolated right atrium. Cardiovasc Res. 1999;43:125-134.
21. Fujita M, Kuwaki T, Ando K, Fujita T. Sympatho-inhibitory action of endogenous adrenomedullin through inhibition of oxidative stress in the brain. Hypertension. 2005;45:1165-1172.
22. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
23. Kleiger RE, Miller JP, Bigger JT, Jr., Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 1987;59:256-262.
24. Zucker IH. Novel mechanisms of sympathetic regulation in chronic heart failure. Hypertension. 2006;48:1005-1011.
25. La Rovere MT, Pinna GD, Hohnloser SH, Marcus FI, Mortara A, Nohara R, Bigger JT, Jr., Camm AJ, Schwartz PJ. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation. 2001;103:2072-2077.
26. Nishime EO, Cole CR, Blackstone EH, Pashkow FJ, Lauer MS. Heart rate recovery and treadmill exercise score as predictors of mortality in patients referred for exercise ECG. J Am Med Assoc. 2000;284:1392-1398.
27. Heaton DA, Li D, Almond SC, Dawson TA, Wang L, Channon KM, Paterson DJ. Gene Transfer of nNOS into Intracardiac Cholinergic Ganglia Reverses Vagal Impairment in Hypertensive Rats. Hypertension. 2007;49:380-388.
28. Cabassi A, Vinci S, Calzolari M, Bruschi G, Borghetti A. Regional sympathetic activity in pre-hypertensive phase of spontaneously hypertensive rats. Life Sci. 1998;62:1111-1118.
29. Huang BS, Leenen FH. Sympathoinhibitory effects of central nifedipine in spontaneously hypertensive rats on high versus regular sodium intake. Hypertension. 1999;33:32-35.
30. Chowdhary S, Townend JN. Nitric oxide and hypertension: not just an endothelium derived relaxing factor! J Hum Hypertens. 2001;15:219-227.
31. Paton JF, Kasparov S, Paterson DJ. Nitric oxide and autonomic control of heart rate: a question of specificity. Trends Neurosci. 2002;25:626-631.
32. Payne JA, Reckelhoff JF, Khalil RA. Role of oxidative stress in age-related reduction of NO-cGMP-mediated vascular relaxation in SHR. Am J Physiol Regul Integr Comp Physiol. 2003;285:R542-R551.
33. Kagota S, Tamashiro A, Yamaguchi Y, Sugiura R, Kuno T, Nakamura K, Kunitomo M. Downregulation of vascular soluble guanylate cyclase induced by high salt intake in spontaneously hypertensive rats. Br J Pharmacol. 2001;134:737-744.
34. Kojda G, Kottenberg K, Hacker A, Noack E. Alterations of the vascular and the myocardial guanylate cyclase/cGMP-system induced by long-term hypertension in rats. Pharm Acta Helv. 1998;73:27-35.
35. Shirasaki Y, Kolm P, Nickols GA, Lee TJ. Endothelial regulation of cyclic GMP and vascular responses in hypertension. J Pharmacol Exp Ther. 1988;245:53-58.
36. Cardillo C, Kilcoyne CM, Cannon RO, 3rd, Panza JA. Attenuation of cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. Circulation. 1999;99:90-95.
37. Lamireau D, Nuyt AM, Hou X, Bernier S, Beauchamp M, Gobeil F Jr., Lahaie I, Varma DR, Chemtob S. Altered vascular function in fetal programming of hypertension. Stroke. 2002;33:2992-2998.
38. Jiang Z, Lei Y, Gu K, Xianghua J, Liming X, Kejian H. The influences of NO and Ach on cGMP levels in two patient populations. J Extra Corpor Technol. 2001;33:23-26.
39. Hamilton CA, Brosnan MJ, McIntyre M, Graham D, Dominiczak AF. Superoxide excess in hypertension and aging: a common cause of endothelial dysfunction. Hypertension. 2001;37:529-534.
40. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, Hamilton CA. Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension. 1999;33:1353-1358.
41. Li YF, Roy SK, Channon KM, Zucker IH, Patel KP. Effect of in vivo gene transfer of nNOS in the PVN on renal nerve discharge in rats. Am J Physiol Heart Circ Physiol. 2002;282:H594-H601.